ArticleNature communications2026
Asymmetric biomimetic transamination of α-keto phosphonates enabled by chiral pyridoxamines and synergistic solvent.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chiral α-aminophosphonate derivatives are recognized as valuable compounds in both medicine and organic chemistry. Biomimetic transamination of α-keto phosphonates represents one of the most efficient strategies for accessing these pharmaceutically relevant molecules. However, establishing a general amine-transfer platform that directly delivers N-unprotected chiral α-aminophosphonates remains challenging. We report an asymmetric transamination of α-keto phosphonates catalyzed by a chiral pyridoxamine catalyst, which efficiently affords a diverse range of chiral α-aminophosphonates with up to 86% yield and 98% ee. This methodology provides a straightforward approach to biologically active α-aminophosphonic acid derivatives. Mechanistic studies, supported by DFT calculations, reveal that trifluoroethanol plays a critical role in determining the enantioselectivity and stabilizing the transition states of the rate-limiting step.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.